Jonathan Alspaugh insider trades: Aeglea BioTherapeutics (AGLE) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jonathan reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 11, 2022 | AGLE | ↑ Buy | 75,000 | $2.08 | $156K | Direct | Mar 15, 2022 (4d) |
| Dec 9, 2021 | AGLE | ↑ Buy | 50,000 | $3.72 | $186K | Direct | Dec 13, 2021 (4d) |
| Aug 18, 2021 | AGLE | ↑ Buy | 40,372 | $6.51 | $263K | Direct | Aug 18, 2021 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jonathan Alspaugh's insider trades
Jonathan Alspaugh is President and CFO at Aeglea BioTherapeutics (AGLE). Since Aug 18, 2021, Jonathan has reported 3 open-market purchases worth $605K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGLE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.